期刊
METHODS
卷 121, 期 -, 页码 130-137出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ymeth.2017.03.007
关键词
CRISPR/Cas9; Cancer model; Tumor suppressor; Oncogene; Tumor heterogeneity; CRISPR-barcoding
资金
- Institut National de la Sante et de la Recherche Medicale (INSERM)
- Universite de Rouen Normandie
- Ligue Contre le Cancer de Normandie
- Normandy Region
- Chair of Excellence program from INSERM
The CRISPR/Cas9 revolution has democratized access to genome editing in many biological fields, including cancer research. Cancer results from the multistep accumulation of mutations that confer to the transformed cells certain biological hallmarks typical of the malignant phenotype. One of the major goals in cancer research is to characterize such mutations and assess their implication in the oncogenic process. Through CRISPR/Cas9 technology, genetic aberrations identified in a patient's tumor can now be easily recreated in experimental models, which can then be used for basic research or for more translational applications. Here we review the different CRISPR/Cas9 strategies that have been implemented to recapitulate oncogenic mutations in both in vitro and in vivo systems, including novel strategies to model tumor evolution and genetic heterogeneity. (C) 2017 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据